Loading…

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2019-01, Vol.19 (1), p.e33-e36
Main Authors:	Iqbal, Shumaila Muhammad, Stecklein, Kathryn, Sarow, Joseph, Krabak, Michael, Hillengass, Jens, McCarthy, Philip
Format:	Article
Language:	English
Subjects:	AL amyloidosis Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7) Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autologous peripheral blood stem cell collection and transplant Dexamethasone - pharmacology Dexamethasone - therapeutic use Female Hematological and organ response Humans Immunoglobulin Light-chain Amyloidosis - drug therapy Lenalidomide - pharmacology Lenalidomide - therapeutic use Middle Aged Multiple Myeloma - drug therapy Nephrotic range proteinuria
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!